Bora CDMO Bora CDMO

X

Find the latest Drugs in Development and Pipeline Prospector News of reMYND.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
reMYND
Belgium Flag
Country
Country
Belgium
Address
Address
Gaston Geenslaan 1 BE-3001 Leuven (Heverlee)
Telephone
Telephone
+32 16 75 14 20
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The ReS3-T program is the result of a collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3). ReS3-T acts via a novel proprietary target, Pde6δ, to control neuronal activity.


Lead Product(s): ReS3-T

Therapeutic Area: Neurology Product Name: ReS3-T

Highest Development Status: PreclinicalProduct Type: Small molecule

Partner/Sponsor/Collaborator: National Institute of Neurological Disorders

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 04, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

RES19-T has shown to produce an acute response, restoring calcium homeostasis and synaptic plasticity, aim to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.


Lead Product(s): RES19-T

Therapeutic Area: Neurology Product Name: RES19-T

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 21, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Proceeds from the fundraise will allow completion of proof-of-concept clinical trials for both the Alzheimer’s and the diabetes programs. A first-in-human trial of RES19-T for Alzheimer’s was initiated in 2020.


Lead Product(s): RES19-T

Therapeutic Area: Neurology Product Name: RES19-T

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Korys Investments

Deal Size: $29.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing January 21, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

RES19-T, a first-in-class small molecule, represents a novel approach to treat Alzheimer’s Disease (AD), aiming to address the disease at its root and restore cognition in patients by reducing the cellular damage associated with memory loss.


Lead Product(s): RES19-T

Therapeutic Area: Neurology Product Name: RES19-T

Highest Development Status: Phase IProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 03, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY